Inactive steroid that is converted into active androgens and/or estrogens. Exact mechanism in treatment of vulvar and vaginal atrophy in menopausal women not fully established.
Therapeutic effects:
Reduced severity of dyspareunia.
Pharmacokinetics⬆⬇
Absorption: Unknown.
Distribution: Unknown.
Metabolism/Excretion: Metabolized via dehydrogenase, reductase, and aromatase to estradiol and testosterone.
Vag (Adults ): Insert one vaginal insert at bedtime.
Availability⬆⬇
Vaginal insert: 6.5 mg
Assessment⬆⬇
Assess for pain during intercourse periodically during therapy.
Assess for current or history of breast cancer prior to use.
Implementation⬆⬇
Insert vaginal insert at bedtime using applicator provided. Vaginal inserts can be stored at room temperature or refrigerated.
Patient/Family Teaching⬆⬇
Explain purpose and side effects of medication. Advise patient to read Patient Information before starting therapy.
Inform patient that vaginal discharge and abnormal PAP smear findings may occur with therapy.
Advise patient to notify health care provider of all Rx or OTC medications, vitamins, or herbal products being taken and to consult with health care provider before taking other medications during therapy.
